MedVellum
MedVellum
Back to Library
Dermatology
Infectious Diseases
Emergency Medicine
Primary Care

Erysipelas

High EvidenceUpdated: 2025-12-22

On This Page

Red Flags

  • Orbital involvement (periorbital erysipelas)
  • Sepsis (fever, tachycardia, hypotension)
  • Rapid spread despite treatment
  • Immunocompromised patient
  • Facial involvement with nasal bridge infection
Overview

Erysipelas

1. Clinical Overview

Summary

Erysipelas is an acute, superficial bacterial skin infection involving the upper dermis and superficial lymphatics. It is almost always caused by Group A Streptococcus (Streptococcus pyogenes). The classic presentation is a well-demarcated, raised, bright red plaque with an advancing, sharply defined border. Unlike cellulitis, erysipelas is more superficial and has clear margins. The face and lower legs are the most common sites. Patients typically present with sudden-onset fever, rigors, and malaise. Treatment is with penicillin-based antibiotics. The prognosis is excellent with appropriate treatment.

Key Facts

  • Organism: Group A Streptococcus (Strep pyogenes) - 80%+
  • Depth: Upper dermis and superficial lymphatics (superficial)
  • Classic Sign: Well-demarcated, raised, bright red plaque
  • Site: Face (20%), Lower leg (70%)
  • Treatment: Penicillin V (oral) or Benzylpenicillin (IV if severe)
  • Prognosis: Excellent with treatment; recurrence common (30%)

Clinical Pearls

"Sharp Edges = Erysipelas, Blurry Edges = Cellulitis": Erysipelas has well-demarcated, raised borders. Cellulitis has indistinct, merging edges. This is the key clinical distinction.

"Fever Comes First": Patients often have rigors and high fever BEFORE the rash appears. This can cause diagnostic confusion.

"The Malar Butterfly": Classic facial erysipelas spares the nasolabial folds and mimics a butterfly pattern, similar to lupus rash - but erysipelas is hot, tender, and the patient is unwell.

"Recurrence is Common": 30% get recurrent erysipelas. Identify and treat predisposing factors (lymphoedema, tinea pedis, venous insufficiency).


2. Epidemiology

Incidence

  • 10-100 per 100,000 per year
  • Higher in elderly and immunocompromised

Demographics

  • Bimodal age distribution: Young children and elderly (>60)
  • Equal M:F (slight female predominance in some studies)

Risk Factors

FactorMechanism
LymphoedemaImpaired lymphatic drainage
Venous insufficiencyStasis, oedema
Tinea pedis (athlete's foot)Entry point for bacteria
Leg ulcersSkin breach
Previous erysipelasDamaged lymphatics
ObesitySkin folds, lymphoedema
ImmunosuppressionDiabetes, HIV, chemotherapy
Injection drug useSkin breaks

Sites

  • Lower legs: 70%
  • Face: 20%
  • Arms: 5%
  • Other: 5%

3. Pathophysiology

Aetiology

OrganismFrequency
Group A Streptococcus80%+
Group G/C Streptococcus10%
Staphylococcus aureusRare (more often in cellulitis)

Mechanism

  1. Entry point: Skin break (tinea pedis, trauma, ulcer, eczema)
  2. Bacterial invasion: Streptococci enter upper dermis
  3. Superficial spread: Rapid horizontal spread through lymphatics
  4. Inflammatory response: Intense local inflammation, cytokine release
  5. Clinical features: Well-demarcated erythema with raised edge

Erysipelas vs Cellulitis

FeatureErysipelasCellulitis
DepthUpper dermis, superficialDeeper dermis and subcutaneous
OrganismGroup A Strep (usually)Staph aureus or Strep
BorderWell-demarcated, raisedIndistinct, merging
Systemic symptomsMore prominent, rapid onsetLess prominent
Surface"Peau d'orange", shinyMay be duller

4. Clinical Presentation

Prodrome

Symptoms

FeatureDescription
RashBright red, hot, tender, rapidly expanding
BordersWell-demarcated, raised (palpable edge)
SurfaceShiny, tense, "peau d'orange" texture
FeverOften high (>8.5°C), with rigors
PainMarked local tenderness

Sites

Face (Malar):

Lower Leg:

Complications Signs


Fever, rigors, malaise (often before rash appears)
Common presentation.
Nausea, vomiting
Common presentation.
5. Clinical Examination

Vital Signs

  • Fever (often >38°C)
  • Tachycardia
  • May be hypotensive if septic

Inspection

  • Bright red, shiny plaque
  • Well-demarcated, raised edge
  • "Peau d'orange" texture (skin pitting)
  • Bullae in severe cases

Palpation

  • Warm to touch
  • Tender
  • Palpable raised edge demarcates from normal skin

Differentiation from Cellulitis

FindingErysipelasCellulitis
EdgePalpable, raised, sharpIndistinct
SurfaceShiny, tenseLess shiny
Systemic symptomsMore markedLess marked

Look for Entry Point

  • Tinea pedis (between toes)
  • Leg ulcer
  • Trauma/abrasions
  • Eczema

6. Investigations

Clinical Diagnosis

  • Usually clinical
  • Blood tests support severity assessment

Blood Tests

TestPurpose
FBCRaised WCC (neutrophilia)
CRPElevated; monitors response
Blood culturesIf septic (positive in only 5%)
U&EAssess renal function, hydration
GlucoseScreen for diabetes

Imaging

  • Usually not required
  • Ultrasound/MRI if concern for deep abscess or necrotizing fasciitis

Microbiology

  • Skin swabs rarely helpful (low yield)
  • Serology (ASOT): Retrospective diagnosis

7. Management

Initial Assessment

┌──────────────────────────────────────────────────────────┐
│   ERYSIPELAS MANAGEMENT                                  │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  ASSESS SEVERITY (Eron Classification):                   │
│                                                          │
│  CLASS I (Mild):                                          │
│  • No systemic toxicity                                  │
│  • No comorbidities                                      │
│  → ORAL antibiotics, outpatient                          │
│                                                          │
│  CLASS II (Moderate):                                     │
│  • Systemically unwell (fever, tachycardia) OR           │
│  • Has comorbidities (diabetes, PVD)                     │
│  → May need initial IV, then step down                   │
│                                                          │
│  CLASS III (Severe):                                      │
│  • Significant systemic upset/sepsis or                  │
│  • Limb-threatening                                      │
│  → IV antibiotics, admission                             │
│                                                          │
│  CLASS IV (Sepsis/NSTI):                                  │
│  • Sepsis syndrome OR                                    │
│  • Necrotizing fasciitis suspected                       │
│  → Urgent IV + surgical review                           │
│                                                          │
└──────────────────────────────────────────────────────────┘

Antibiotic Treatment

SeverityAntibioticDuration
Mild (oral)Phenoxymethylpenicillin (Penicillin V) 500mg QDS7-14 days
Alternative (allergy)Clarithromycin 500mg BD7-14 days
Moderate/Severe (IV)Benzylpenicillin 1.2g QDSStep down when improving
Severe/septicBenzylpenicillin + FlucloxacillinAs per microbiologist

Supportive Care

  • Elevate affected limb (reduces oedema)
  • Mark edge with skin marker (monitor spread)
  • Analgesia (paracetamol, ibuprofen)
  • Hydration
  • Treat entry point (e.g., tinea pedis)

Follow-Up

  • Review at 48-72 hours
  • Assess response (reducing erythema, fever settling)
  • Identify predisposing factors for recurrence prevention

8. Complications

Acute

  • Abscess formation
  • Sepsis
  • Deep vein thrombosis (immobility)
  • Necrotizing fasciitis (rare but serious)

Chronic

  • Recurrent erysipelas (30%)
  • Lymphoedema (damaged lymphatics)
  • Post-inflammatory hyperpigmentation

9. Prognosis & Outcomes

With Treatment

  • Excellent prognosis
  • Most improve within 48-72 hours
  • Full resolution within 1-2 weeks

Recurrence

  • 30% recurrence rate
  • Prevention: Treat underlying factors, prophylactic antibiotics if recurrent

Prophylaxis for Recurrent Erysipelas

  • Penicillin V 250mg BD long-term (or Erythromycin if allergic)
  • Reduces recurrence by 50%

10. Evidence & Guidelines

Key Guidelines

  1. NICE CKS: Cellulitis and Erysipelas
  2. CREST Guidelines: Management of Cellulitis
  3. British Dermatology Guidelines

Key Evidence

Antibiotics

  • Penicillin remains first-line (Group A Strep sensitivity)
  • No proven benefit of anti-staphylococcal agents in typical erysipelas

Prophylaxis

  • RCTs show long-term penicillin reduces recurrence by ~50%

11. Patient/Layperson Explanation

What is Erysipelas?

Erysipelas is a skin infection caused by bacteria, usually streptococcus ("strep"). It causes a bright red, hot, swollen area on the skin with a clearly defined edge. It most commonly affects the face or lower legs.

What Causes It?

Bacteria enter through a break in the skin, such as:

  • Athlete's foot (cracked skin between toes)
  • Cuts or grazes
  • Leg ulcers
  • Eczema

What Are the Symptoms?

  • Sudden onset of fever, chills, and feeling unwell
  • A bright red, painful, swollen area of skin
  • The edge of the redness is clearly defined and raised
  • The affected area feels hot

How is it Treated?

Antibiotics are very effective. Most people get oral antibiotics to take at home. If you're very unwell, you may need antibiotics through a drip in hospital.

You should also:

  • Rest with the affected limb raised
  • Take paracetamol for pain and fever
  • Drink plenty of fluids

How Long Does it Take to Get Better?

You should start to feel better within 2-3 days. The redness may take 1-2 weeks to completely disappear.

Can it Come Back?

Yes, about 1 in 3 people get erysipelas again, especially if there's an underlying problem like lymphoedema or athlete's foot. Treating these conditions helps prevent recurrence.


12. References

Primary Guidelines

  1. NICE Clinical Knowledge Summaries. Cellulitis and Erysipelas. cks.nice.org.uk
  2. CREST Guidelines. Guidelines on the Management of Cellulitis in Adults. 2005.

Key Studies

  1. Sjöblom AC, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21(6):390-393. PMID: 8132368
  2. Morris AD. Cellulitis and erysipelas. BMJ Clin Evid. 2008. PMID: 19450314

Last updated: 2025-12-22

At a Glance

EvidenceHigh
Last Updated2025-12-22

Red Flags

  • Orbital involvement (periorbital erysipelas)
  • Sepsis (fever, tachycardia, hypotension)
  • Rapid spread despite treatment
  • Immunocompromised patient
  • Facial involvement with nasal bridge infection

Clinical Pearls

  • **"Sharp Edges = Erysipelas, Blurry Edges = Cellulitis"**: Erysipelas has well-demarcated, raised borders. Cellulitis has indistinct, merging edges. This is the key clinical distinction.
  • **"Fever Comes First"**: Patients often have rigors and high fever BEFORE the rash appears. This can cause diagnostic confusion.
  • **"The Malar Butterfly"**: Classic facial erysipelas spares the nasolabial folds and mimics a butterfly pattern, similar to lupus rash - but erysipelas is hot, tender, and the patient is unwell.
  • **"Recurrence is Common"**: 30% get recurrent erysipelas. Identify and treat predisposing factors (lymphoedema, tinea pedis, venous insufficiency).

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines